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676Low Urinary Creatinine Excretion Is Associated
With Self-Reported Frailty in Patients With
Advanced Chronic Kidney Disease
Harmke A. Polinder-Bos1, Hakan Nacak2, Friedo W. Dekker2, Stephan J.L. Bakker1,
Carlo A.J.M. Gaillard1 and Ron T. Gansevoort1
1Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen,
Groningen, the Netherlands; and 2Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The
NetherlandsIntroduction: Frailty and muscle wasting, a component of frailty, are common in advanced stage chronic
kidney disease (CKD). Whether frailty is associated with low urinary creatinine excretion (UCrE) as a
measure of muscle mass in this population is unknown. Furthermore, reference values of UCrE are lacking.
We ﬁrst deﬁned low UCrE and studied correlates of low UCrE, and subsequently studied cross-sectional
associations of frailty with low UCrE in patients with advanced CKD.
Methods: A total of 2748 healthy individuals of the general population-based PREVEND study were
included to deﬁne low UCrE (UCrE indexed for height, below the age- and sex-speciﬁc 5th percentile of the
distribution). Frailty was deﬁned using a modiﬁcation of the Fried frailty phenotype. In a CKD population
that included 320 and 967 participants of the PREPARE-2 and NECOSAD studies, respectively, cross-
sectional associations of self-reported frailty, the individual components that deﬁne self-reported frailty,
and frailty-associated variables with low UCrE were evaluated using multivariate logistic and linear
regression models.
Results: Low UCrE was found in 38% of the CKD patients. A lower glomerular ﬁltration rate
was strongly associated with low UCrE. Self-reported frailty (adjusted odds ratio: 2.19; 95% conﬁ-
dence interval: 1.283.77) and the individual components were associated with low UCrE,
independent of comorbidities. The frailty-associated variables hemoglobin and albumin were
inversely associated with low UCrE, and parathyroid hormone was positively associated with low
UCrE.
Discussion: Lower kidney function is a strong correlate of low UCrE and self-reported frailty, and the in-
dividual frailty components are associated with low UCrE as well, independent of comorbidities.
Kidney Int Rep (2017) 2, 676–685; http://dx.doi.org/10.1016/j.ekir.2017.02.021
KEYWORDS: chronic kidney disease; creatinine; frailty; muscle
ª 2017 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).U rinary creatinine excretion (UCrE), measured by24-hour urine sampling, is an established marker
of muscle mass in individuals at steady state.1–7 Low
UCrE has been recognized as a predictor of mortality
and adverse health outcomes in patients with stage 3
to 5 chronic kidney disease (CKD) and various other
populations.7–13 However, the link between low muscle
mass and adverse health outcomes remains unclear. Ex-
planations include that low UCrE reﬂects worse musclespondence: Harmke A. Polinder-Bos, Department of
ology, University Medical Center Groningen, University of
ngen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
l: H.A.Polinder-Bos@umcg.nl
ved 15 July 2016; revised 6 February 2017; accepted 28
ary 2017; published online 9 March 2017health, or is related to chronic low-grade inﬂammation,
insulin resistance, or protein caloric malnutrition. We
hypothesize that frailty is related to low UCrE because
low muscle mass is an important component of frailty,
and especially of the physical frailty deﬁnition.14
Frailty is common in patients with advanced CKD
and has been associated with earlier need for dialysis
initiation, lower quality of life, and increased mortality
risk.15–20 CKD has been hypothesized as an accelerator
of decline of physical function that leads to frailty.21–23
However, whether frailty is associated with a low UCrE
in advanced CKD has not yet been studied. Further-
more, reference values of UCrE are lacking. Therefore,
we ﬁrst aimed to determine low UCrE by using the
UCrE distribution of a healthy population and subse-
quently evaluate correlates of low UCrE. Second, weKidney International Reports (2017) 2, 676–685
HA Polinder-Bos et al.: Urinary Creatinine Excretion and Frailty in CKD CLINICAL RESEARCHaimed to evaluate associations of self-reported frailty,
the individual components that deﬁne self-reported
frailty, and frailty-associated variables with low UCrE
in a cohort of patients with advanced CKD.
MATERIALS AND METHODS
Study Design and Population
To deﬁne low UCrE values, we included as a healthy
population a subsample representative of the general
population (n ¼ 3432) of the Prevention of Renal and
Vascular End-Stage Disease (PREVEND) study. This pro-
spective, population-based cohort study investigated the
natural course of urinary albumin excretion and its rela-
tion to renal and cardiovascular disease. Detailed infor-
mation on the design of the PREVEND study has been
published previously.24 In summary, all inhabitants of the
city of Groningen aged 28 to 75 years were sent a ques-
tionnaire and a vial to collect a ﬁrst-morning urine sample.
We excluded pregnant women and subjects with diabetes
mellitus type 1 from the 40,856 respondents, and 2 cohorts
were formed based on urinary albumin concentration.
From these 2 cohorts, a subsample of 3432 subjects was
derived that was representative of the general population.
From this subsample, we excluded participants with no
UCrE available, no serum creatinine and/or height avail-
able, those with comorbid conditions, or those aged
younger than 25 years, which left 2892 participants for the
present study. Participants with missing UCrE values did
not differ signiﬁcantly from participants for whom UCrE
valueswere available. The PREVEND studywas approved
by the institutional reviewboard, and all participants gave
written informed consent.
The CKD population included participants of
the multicenter observational PREdialysis PAtients
REcords-study (PREPARE-2) and NEtherlands COoper-
ative Study on the Adequacy of Dialysis (NECOSAD)
studies. PREPARE-2 included 502 patients with stage
4 CKD aged 18 years or older who were treated by a
nephrologist and had recently been referred to a
specialized predialysis outpatient clinic. All patients had
to be suitable for renal replacement therapy. Patients
with chronic transplantation dysfunction were
excluded from the study if the transplant was within the
previous year. NECOSAD included 2051 patients with
stage 5 CKDwhowere starting dialysis. To be eligible for
inclusion in NECOSAD, adult patients (age 18 years or
older) had to start with dialysis as their ﬁrst renal
replacement therapy. No other inclusion or exclusion
criteria were applied. The institutional review boards of
all participating hospitals approved the studies. All
patients gave written informed consent. Detailed infor-
mation on the design of the PREPARE-2 and NECOSAD
studies has been published previously.25,26Kidney International Reports (2017) 2, 676–685For this present study, we included 340 and 1055
participants of PREPARE-2 and NECOSAD respectively,
aged between 25 years or older and 85 years and
younger, for whom height and UCrE were available, and
UCrE was collected before dialysis initiation (NECO-
SAD). In PREPARE-2, patients withmissing UCrE values
had a higher estimated glomerular ﬁltration rate
(eGFR), according to the Modiﬁcation of Diet in Renal
Disease Study equation, compared with patients for
whom UCrE values were available (16.2 ml/min/1.73 m2
vs. 13.9 ml/min/1.73 m2, respectively; P¼ 0.03), a lower
median albumin (39 g/L vs. 42 g/L, respectively;
P < 0.001), and were less likely to have low physical
performance (53% vs. 65%; P ¼ 0.03). In NECOSAD,
patients with missing UCrE values were slightly
older (median age 64.4 years vs. 61.9 years; P ¼ 0.004),
had lower hemoglobin values (median 6.3 mmol/L vs.
6.4 mmol/L; P¼ 0.02), higher eGFRModiﬁcation of Diet
in Renal Disease Study values (median 7.0 ml/min/
1.73 m2 vs. 6.7 ml/min/1.73 m2; P ¼ 0.02), and lower
albumin values (median 35 g/L vs. 37 g/L; P < 0.001).
Frailty
Self-reported frailty was deﬁned similarly to a
frequently used modiﬁcation of Fried’s criteria
for frailty developed by Woods et al.27 and Johansen
et al.27–31 Physical weakness and slowness was deﬁned
as a score <75 on the physical functioning scale of the
Short Form of Health Survey-36. Exhaustion was
deﬁned as a score <55 on the vitality scale of the Short
Form of Health Survey-36. A body mass index
(BMI) <18.5 kg/m2 was used as a substitute for un-
intentional weight loss.19 Because underweight is a
more accurate description of this modiﬁed criterion,
the unintentional weight loss criterion is used as
“underweight” hereafter. Physical inactivity was
deﬁned as the combination of self-reported moderate
or extreme walking problems, with moderate or
extreme usual activities limitations according the
EuroQol 5-dimensional (EQ-5D) questionnaire.32 A to-
tal of 5 points was possible, with 2 points for low
physical functioning and 1 point for each of the other
criteria. Patients scoring $3 were deﬁned as frail ac-
cording to the literature.14,27,30 For NECOSAD pa-
tients, the Short Form of Health Survey-36 and EQ-5D
questionnaire had to be completed before dialysis
initiation or within 7 days from the start of dialysis. In
an additional analysis, we studied the association of
prefrailty (a self-reported frailty score of 1 or 2) with
low UCrE. Patients in whom all frailty data were
available were slightly different from those patients in
whom not all frailty data were available. Therefore,
patients in whom frailty was available had higher677
CLINICAL RESEARCH HA Polinder-Bos et al.: Urinary Creatinine Excretion and Frailty in CKDmean levels of UCrE (9.6 mmol/24 hours vs. 8.4 mmol/
24 hours; P < 0.001), a higher BMI (26.4 kg/m2 vs.
25.2 kg/m2; P < 0.001), and higher levels of GFR
(12.5 ml/min vs. 9.5 ml/min; P < 0.001), hemoglobin
(7.5 mmol/L vs. 6.6 mmol/L; P < 0.001), and albumin
(40 g/L vs. 37 g/L; P < 0.001).
Frailty-Associated Variables
Frailty-associated variables included cigarette smok-
ing, albumin, parathyroid hormone, hemoglobin,
protein-energy wasting according to the Subjective
Global Assessment total score, and the Charlson Co-
morbidity Index. The Charlson Comorbidity Index
was divided into 3 tertiles: 1: 0 to 2; 2: 3 to 5; and 3: 6
to 10.
Laboratory and Other Measurements
Standard laboratory techniques were used in the
different centers participating in the PREPARE-2,
NECOSAD, and PREVEND studies. GFR was calcu-
lated as the mean of urea and creatinine clearance,
measured from 24-hour urine collections. The
abbreviated Modiﬁcation of Diet in Renal Disease
Study equation was used to measure eGFR.
Educational levels were categorized according to
the International Standard Classiﬁcation of Education
as bachelor, master or doctorate graduate (level 1),
postsecondary or nontertiary or short-cycle tertiary
education (level 2), upper secondary education
(level 3), lower secondary education (level 4), and
primary or less than primary education (level 5).33
Malignancy (n ¼ 82) was deﬁned as a history of
(83%) or active (treated or untreated) malignancy
(17%). The skin tumors squamous cell carcinoma and
basal cell carcinoma were excluded for the deﬁnition
of malignancy.
Statistical Analyses
Differences between patients with low UCrE versus
normal range UCrE were tested for statistical signiﬁ-
cance using Student’s t-test, Mann-Whitney test, or c2
test, as appropriate.
Low UCrE was deﬁned stratiﬁed by sex, then
indexed by height (UCrE/height); we subsequently
calculated the 5th and 95th percentiles per 5-year age
category. These values were plotted, and a third-order
polynomial regression line was chosen, because this
model yielded the highest R2 values. UCrE was
indexed by height, because muscle mass is highly
dependent on body size. All height-indexed UCrE
values in patients with CKD that were below the 5th
percentile of the healthy population were deﬁned as
low.678Logistic regression was used to identify correlates of
low UCrE, presented in (i) crude analyses; (ii) analyses
adjusted for age, race, sex, and height; and (iii) analyses
with all variables added in 1 model. Furthermore, lo-
gistic regression was used to evaluate the associations
of the frailty variables with low UCrE. These models
are presented as (i) crude, and then adjusted for (ii)
comorbidities, and (iii) GFR, using both the linear and
quadratic function of GFR to allow for nonlinear asso-
ciations. Adjustment for GFR was performed to model
the effect of kidney function on both frailty and low
UCrE. A subsidiary multivariate linear regression
analysis was performed with UCrE treated as a
continuous variable.
Subjects with UCrE values that were biologically
implausible (UCrE <3.09 or >30.9 mmol/day) were
excluded.34 Furthermore, patients with the 5% greatest
differences between measured UCrE and calculated
UCrE were excluded. For this purpose, we calculated
the estimated UCrE by multiplying creatinine clearance
(according to the Cockroft-Gault formula) with plasma
creatinine.
Missing values of variables that were used for
adjustment were imputed with standard multiple
imputation techniques using 10 repetitions. Informa-
tion on chronic lung disease and malignancy was
missing in 31% of cases due to availability in the
NECOSAD study only. Information on urea clearance
was missing in 42% of cases. The multiple imputation
model included the characteristics described in
Table 1.
Several sensitivity analyses were performed. First,
we repeated the analyses without excluding subjects
with UCrE values <3.09 or >30.9 mmol/day. Second,
we repeated the analyses in complete cases. Third, we
tested potential interactions of the frailty variables
with the original study cohort. Subsequently, we
repeated the analyses in the PREPARE-2 and NECOSAD
cohorts separately.
A P value < 0.05 was considered statistically sig-
niﬁcant. All analyses were performed in SPSS (version
22.0; IBM, Armonk, New York).
RESULTS
Study Participants
The healthy control group included 2748 PREVEND
participants, after excluding subjects with UCrE
values that were biologically implausible
(UCrE <3.09 or >30.9 mmol/day) and excluding pa-
tients with the 5% highest differences between
measured UCrE and calculated UCrE. The CKD pop-
ulation ﬁnally included 320 PREPARE-2 and 967
NECOSAD participants, after applying the sameKidney International Reports (2017) 2, 676–685









UCrE in men (mmol/24 h) 9.4 (7.611.4) 7.5 (6.38.5) 11.0a (9.712.4)
UCrE in women
(mmol/24 h)
6.9 (5.78.4) 5.2 (4.76.1) 8.0a (6.89.2)
Demographics
Age (yr) 63.1 (51.972.4) 62.5 (51.670.4) 64.2b (5274.1)
Men (%) 63 67 60c
Non-Caucasian race (%) 8 9 7
Primary kidney disease (%)
Glomerulonephritis 13 10 15
Diabetes Mellitus 15 18 14
Renal vascular disease 19 18 18
Other 53 53 53
Educational level (%)
Level 1 5 5 6
Level 2 9 9 9
Level 3 18 19 17
Level 4 42 43 42
Level 5 26 25 26




24.8 (22.527.9) 23.6 (21.526.1) 25.7a (23.328.7)
Length (cm) 171.3  9.7 171.4  9.3 171.3  9.9
Weight (kg) 74.0 (6584) 70.7 (6279) 76.9a (6787)
Comorbidities (%)
Myocardial infarction 13 15 12
Heart failure 12 15 10c




CVA 10 9 9
Malignancy 9 10 9
Chronic lung disease 7 9 6
Charlson Comorbidity Index
Class 1 32 34 33
Class 2 32 30 32
Class 3 36 36 35
Laboratory results
eGFR (ml/min/1.73 m2) 8.0 (5.811.4) 7.1 (5.510.0) 8.3a (6.112.5)
GFR (ml/min) 9.5 (7.312.3) 7.4 (5.69.2) 11.2a (8.914.0)
Hemoglobin (mmol/L) 6.8  1.1 6.5  1.1 7.0  1.2a
Albumin (g/L) 38 (3442) 36 (3140) 39a (3543)
PTH (pmol/L) 17.8 (1028.1) 18.3 (8.346.9) 16.9 (10.027.1)
SGA total score (%)
15 ¼ severe to
moderate PEW
9 17 9
67 ¼ normal nutritional
status
91 83 92
CVA, cerebrovascular accident; DM, diabetes mellitus; GFR, glomerular ﬁltration rate;
PEW, protein-energy wasting; PTH, parathyroid hormone; SGA, subjective global
assessment of nutritional status; UCrE, urinary creatinine excretion.
Data are given as mean  SD or median (interquartile range).
Charlson Comorbidity Index: class 3 indicating the highest comorbidity burden.
Educational level: level 1 ¼ university, level 5 ¼ primary school or less.



















































Figure 1. Low urinary creatinine excretion in (a) male and (b) female
patients with advanced CKD. Dashed line represents the 95th
percentile, and the solid line represents the 5th percentile of urinary
creatinine excretion (UCrE) values in a healthy population.
HA Polinder-Bos et al.: Urinary Creatinine Excretion and Frailty in CKD CLINICAL RESEARCHexclusion methods as the healthy cohort to exclude
possibly incorrectly measured UCrE values. Patient
characteristics according to study population are
shown in Supplementary Table 1.Kidney International Reports (2017) 2, 676–685Deﬁnition of Low UCrE
The regression equation of the 5th percentile of UCrE
values was modeled as follows:
UCrE=height ðmÞ 5th percentile ¼
ð0:0338 age3þ 4:8107 age2 240:54 ageþ 8462:7Þ=1000 ðwomenÞ
ð0:111 age3 þ 17:185 age2  869:31 ageþ 19; 838Þ=1000 ðmenÞ
The ﬁt of the regression model and the ﬁts of the other
models that were tested are shown in Supplementary
Table 2, and the ﬁt of the regression model is further visu-
alized in Supplementary Figures 1a and 1b. Of the CKD pa-
tients, 38% had a low UCrE value according to the 5th
percentile of the healthy population (Figures 1a and 1b). Of
the patients with low UCrE, 88% originated from the
NECOSAD study. Patients with low UCrE had a lower BMI,
lower albumin, hemoglobin, and eGFR levels, compared with
patients with a normal UCrE (Table 1).
Potential Correlates of Low UCrE
Crude odds of low UCrE were signiﬁcantly higher in
men, smokers, patients with heart failure, patients with
peripheral vascular disease, and patients with lower
GFR (Table 2). Excluding patients with peripheral
vascular disease deﬁned as an amputation (n ¼ 14)
yielded similar results (model 3: odds ratio [OR]: 1.88;
95% conﬁdence interval [CI]: 1.133.12; P ¼ 0.01).679
Table 2. Potential correlates of low urinary creatinine excretion
Model 1 Model 2 Model 3
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age (yr)
<48.4 (ref)
48.559.3 1.26 0.881.79 0.21 1.24 0.871.77 0.24 1.20 0.731.97 0.48
59.467.35 1.43 1.0022.03 0.05 1.33 0.931.91 0.12 1.40 0.842.34 0.20
67.3674.07 1.30 0.911.86 0.14 1.23 0.851.76 0.27 0.88 0.511.51 0.63
$74.1 0.50 0.340.73 <0.001 0.45 0.300.67 <0.001 0.31 0.170.57 <0.001
Male gender 1.31 1.031.66 0.03 1.66 1.212.27 0.002 2.07 1.323.25 0.002
Race
Caucasian (ref)
NonCaucasian 1.24 0.831.86 0.30 1.07 0.701.64 0.75 0.97 0.521.80 0.92
Educational level
Level 1
Level 2 0.96 0.531.74 0.89 0.80 0.431.50 0.48 0.88 0.401.93 0.75
Level 3 1.07 0.671.73 0.77 0.90 0.541.50 0.69 1.06 0.562.01 0.86
Level 4 1.17 0.801.71 0.41 1.07 0.711.61 0.76 1.67 0.982.83 0.06
Level 5 1.05 0.771.42 0.78 0.95 0.701.32 0.77 1.00 0.661.51 0.99
Primary kidney disease
Glomerulonephritis (ref)
DM 2.16 1.393.35 0.001 2.30 1.463.62 <0.001 3.02 1.287.09 0.01
Renovascular disease 1.58 1.042.41 0.03 1.77 1.142.75 0.01 2.27 1.224.24 0.01
Other 1.56 1.082.26 0.02 1.75 1.202.55 0.004 1.94 1.183.21 0.009
Smoking 1.38 1.061.78 0.02 1.33 1.021.74 0.04 1.36 0.951.96 0.10
GFR quartiles (ml/min)
1st (1.65.3) 25.8 16.041.8 <0.001 33.2 20.055.1 <0.001 41.4 22.576.2 <0.001
2nd (5.37.2) 6.15 3.959.55 <0.001 7.13 4.5011.3 <0.001 9.03 5.2115.7 <0.001
3rd (7.29.6) 2.26 1.363.78 0.002 2.29 1.353.87 0.002 2.35 1.264.38 0.008
4th (9.632.4) (ref)
Myocardial infarction 1.33 0.941.88 0.10 1.29 0.901.85 0.17 1.34 0.792.29 0.28
Heart failure 1.47 1.042.08 0.03 1.63 1.132.37 0.009 1.29 0.742.25 0.36
DM 1.25 0.951.64 0.11 1.28 0.961.70 0.09 1.14 0.592.21 0.70
Peripheral vascular disease 1.37 1.001.87 0.05 1.45 1.042.01 0.03 1.73 1.062.83 0.03
CVA 0.90 0.611.34 0.61 0.90 0.601.35 0.61 1.06 0.611.85 0.84
Malignancy 1.04 0.671.62 0.86 1.09 0.681.75 0.72 1.11 0.602.07 0.73
Chronic lung disease 1.47 0.852.54 0.17 1.48 0.852.58 0.17 2.06 1.034.14 0.04
CI, conﬁdence interval; CVA, cerebrovascular accident; DM, diabetes mellitus; GFR, glomerular ﬁltration rate; OR, odds ratio.
The dependent variable in the analyses is low urinary creatinine excretion.
Model 1 ¼ crude; Model 2 ¼ adjusted for age, race, sex, and height; Model 3 ¼ all variables added in 1 model.
Educational level: level 1 ¼ university; level 5 ¼ primary school or less.
CLINICAL RESEARCH HA Polinder-Bos et al.: Urinary Creatinine Excretion and Frailty in CKDRemarkably, patients in the oldest age quintile showed
signiﬁcant lower odds of low UCrE compared with the
youngest age quintile (OR: 0.31; 95% CI: 0.170.57;
P < 0.001). A low GFR was the strongest correlate of
low UCrE in model 3. Compared with patients with
glomerulonephritis (GN) as a primary cause of renal
disease, patients with other primary causes of renal
disease (e.g., diabetes mellitus, hypertension) were
more likely to have low UCrE.
Self-Reported Frailty and Low UCrE
All the individual items of the self-reported frailty
deﬁnition were available for 353 patients, 56% of
whom were categorized as frail. Of the individual
frailty components, physical inactivity was present in
42%, exhaustion and/or fatigue in 55%, low physical680functioning in 66%, and underweight in 3% of the
patients.
Self-reported frailty, and all the individual compo-
nents that deﬁne self-reported frailty, were signiﬁ-
cantly associated with low UCrE (Table 3). Of the
individual components, underweight yielded the
highest odds of low UCrE (crude OR: 3.75; 95% CI:
1.767.98; P ¼ 0.001). Adjustment for comorbidities in
model 2 did not change the results. Additional
adjustment for GFR in model 3 attenuated most asso-
ciations, except for albumin and the individual
component underweight. Similar results were obtained
when UCrE was modeled as a continuous outcome
(Supplementary Table 3). An additional analysis
showed that prefrailty was associated with low UCrE
with similar odds in models 1 and 2.Kidney International Reports (2017) 2, 676–685
Table 3. Associations of frailty, the individual components, and frailty-associated variables with low urinary creatinine excretion
Model 1 Model 2 Model 3
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Frailty (n ¼ 353) 2.11 1.253.54 0.005 2.19 1.283.77 0.005 1.65 0.863.15 0.13
Individual frailty components
Poor physical performance (n ¼ 364) 1.36 1.041.79 0.03 1.35 1.021.79 0.04 1.31 0.931.84 0.12
Exhaustion/fatigue (n ¼ 371) 2.37 1.423.96 0.001 2.40 1.414.08 0.001 1.79 0.963.35 0.07
Underweight (n ¼ 1281) 3.75 1.767.98 0.001 3.86 1.808.28 0.001 4.26 1.7410.4 0.002
Physical inactivity (n ¼ 376) 1.72 1.062.78 0.03 1.79 1.082.97 0.02 1.42 0.772.59 0.26
Frailtyassociated variables
Hemoglobin (mmol/L) (n ¼ 927) 0.70 0.620.79 <0.001 0.70 0.620.79 <0.001 1.12 0.951.31 0.18
Albumin (g/L) (n ¼ 1182) 0.92 0.910.94 <0.001 0.93 0.910.95 <0.001 0.97 0.950.998 0.03
PTH (per 10 pmol/L) (n ¼ 251) 1.14 1.001.29 0.05 1.16 1.021.33 0.03 1.04 0.911.20 0.57
Charlson Comorbidity Index (n ¼ 905)
Class 1 (ref)
Class 2 1.11 0.801.55 0.53 0.99 0.791.39 0.94 0.92 0.611.37 0.67
Class 3 1.25 0.911.71 0.28 0.75 0.471.20 0.23 0.64 0.361.11 0.11
Moderate to severe PEW (n ¼ 260) 2.22 0.905.47 0.08 2.22 0.905.65 0.10 1.43 0.484.28 0.53
CI, conﬁdence interval; OR, odds ratio; PEW, protein-energy wasting according the Subjective Global Assessment of nutritional status; PTH, parathyroid hormone.
The dependent variable in the analyses is low urinary creatinine excretion.
Model 1 ¼ crude; Model 2 ¼ model 1 þ adjusted for heart failure, diabetes mellitus, myocardial infarction , peripheral vascular disease, cerebrovascular accident, malignancy, and
chronic lung disease; Model 3 ¼ model 2 þ glomerular ﬁltration rate. Charlson Comorbidity Index: class 3 indicating the highest comorbidity burden.
HA Polinder-Bos et al.: Urinary Creatinine Excretion and Frailty in CKD CLINICAL RESEARCHSensitivity Analyses
First, including subjects with UCrE values <3.09
or >30.9 mmol/day yielded similar results for the
analysis of potential correlates of low UCrE, and for
the analysis of self-reported frailty and low UCrE.
Second, the results remained essentially similar when
repeating the analyses with complete cases. Third, no
signiﬁcant interaction was found between the original
study cohort and 1 of the frailty variables. Repeating
the analyses in the PREPARE-2 and NECOSAD cohorts
separately yielded essentially similar results, but did
not reach signiﬁcance in the NECOSAD cohort due
to lower power because the frailty variables were
available more often in patients in PREPARE-2
(n ¼ 243) than in patients in NECOSAD (n ¼ 110)
(Supplementary Tables 4–7).
DISCUSSION
This study showed that self-reported frailty, all the
individual components that deﬁne self-reported frailty,
and the frailty-associated variables hemoglobin, albu-
min, and parathyroid hormone were associated with
low UCrE, independent of comorbidities. Furthermore,
we found that low UCrE was present in more than one-
third of patients with advanced CKD, and was strongly
related to a lower kidney function level.
To the best of our knowledge this was the ﬁrst study
to investigate the associations of self-reported frailty
with low UCrE as a measure of low muscle mass, which
showed that self-reported frailty is associated with low
UCrE. Although frailty has not been related to low
UCrE yet, frailty has been associated with other mea-
sures of muscle mass. In a population of olderKidney International Reports (2017) 2, 676–685community-dwelling adults, a high calf circumference
was associated with a lower level of frailty, better
muscle strength, and better performance on the Short
Physical Performance Battery.35 Associations of frailty
with lower quadriceps muscle area or with intracellular
water as a measure of muscle mass have been reported
in the hemodialysis population.36,37
Low UCrE was prevalent in 38% of the patients with
advanced CKD, and the prevalence was higher in pa-
tients with lower GFR values, which suggested an ef-
fect of CKD on muscle mass. This ﬁnding was in
accordance with 2 previous studies that found lower
UCrE per increasing CKD stage,8 and a decrease in UCrE
with declining kidney function over time, independent
of nutritional factors.38 Furthermore, a lower kidney
function was associated with muscle atrophy, reduced
walking speed, and more rapid declines in lower ex-
tremity strength over time.39 Studies that used other
methods to measure muscle mass found the same as-
sociation of impaired kidney function and low muscle
mass.7,21,40,41 Low UCrE might be a reﬂection of not
only muscle mass, but also of low muscle function.
Wilson et al. showed a lower creatinine generation rate
per kilogram of skeletal muscle mass, measured as a fat-
free mass by bioelectrical impedance analysis in those
with lower GFR.7 This lower creatinine generation rate
might be explained by altered muscle metabolism
in advanced CKD that leads to lower UCrE and poorer
muscle function. This hypothesis was favored by
the recent study by Marcus et al., which showed that
poor physical function in hemodialysis patients was
not explained by low muscle mass or comorbid
conditions.42681
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why UCrE is lower in later stage CKD. The lower UCrE
could to some extent be explained by an increase in
extrarenal clearance of creatinine.43,44 Extrarenal
clearance of creatinine was investigated in only 2
studies, which included a maximum of 10 patients each
and reported a wide range of extrarenal clearance.45,46
Most importantly, they did not measure muscle mass
simultaneously, nor did they investigate the association
between extrarenal clearance of creatinine and kidney
function. Therefore, the degree of extrarenal clearance
in relation to impaired kidney function is unknown.
The mechanisms that cause loss of muscle mass in
CKD are incompletely understood. Muscle loss occurs
either because of increased muscle protein breakdown
or decreased muscle protein synthesis or a combination
of both. Reduced muscle protein synthesis has been
found in CKD.47 Increased muscle protein breakdown is
a result of increased catabolic processes, which can be
the result of several CKD-associated conditions such as
chronic inﬂammation, uremia, acidosis, decline of
insulin-like growth factor 1, alterations in vitamin D,
and protein-energy wasting.22,48,49 Low physical ac-
tivity, which is common in patients who start dial-
ysis,50 induces loss of muscle mass as well. However,
these mechanisms that cause loss of muscle mass in CKD
are beyond the scope of this present study.
Remarkably, the associations of underweight and
albumin with low UCrE were independent of GFR.
Similarly, Tynkevich et al. described a strong associa-
tion of a BMI <18.5 kg/m2 with low UCrE indepen-
dently of measured GFR in patients with advanced
CKD.38 These ﬁndings suggested a strong direct effect
of underweight on muscle mass, not via chronic kidney
disease per se, whereas the associations of other phys-
ical frailty components such as poor physical perfor-
mance, exhaustion, and physical inactivity with low
UCrE might be caused by reduced GFR, and the com-
plications of CKD (e.g., metabolic acidosis, inﬂamma-
tion) more directly. Therefore, our hypothesis is that a
reduced GFR leads to muscle wasting, both directly,
and indirectly via weakness, slowness, physical inac-
tivity, and exhaustion. Furthermore, the inﬂammation
and other complications of advanced CKD might also
contribute to loss of muscle mass.
Concerning the potential correlates of low UCrE, a
remarkably lower risk of a low UCrE in patients with
CKD aged 74 years and older was found. This lower
risk might be explained by selection bias of a relatively
healthier older population that was admitted to initiate
dialysis therapy. Nephrologists might have been more
cautious to refer elderly CKD patients in a poor phys-
ical condition to specialized predialysis outpatient
clinics (PREPARE-2) or to initiate dialysis (NECOSAD)682compared with younger CKD patients. Furthermore, a
remarkable ﬁnding was a higher odds of low UCrE in
men compared with women. There are several expla-
nations. First, relatively more frail male patients might
have been selected to initiate dialysis therapy
compared with female patients. Second, CKD might
have a larger impact on muscle mass in male patients
compared with female patients. Non-GN causes of renal
failure were signiﬁcantly associated with low UCrE
compared to GN. This ﬁnding might be explained by a
higher comorbidity burden in the non-GN patients
(e.g., hypertension, diabetes and cardiovascular dis-
eases) and the fact that these comorbidities would
result in a higher prevalence of frailty and low UCrE.31
This study used a self-reported deﬁnition of frailty,
which was used in previous studies, except for the
deﬁnition of low physical activity.27–31 This self-
reported frailty deﬁnition was similar to a frequently
used modiﬁcation of the Fried frailty phenotype, which
is based on 5 physical criteria. We modiﬁed the deﬁ-
nition of low physical activity by using items of the EQ-
5D, which yielded a similar percentage of patients who
were physically inactive (42%) compared with other
(advanced) CKD populations (36%54%).17–19,30,51
Johansen et al. compared physical functioning accord-
ing to the self-reported frailty deﬁnition with gait
speed and grip strength in hemodialysis patients.
Self-reported frailty identiﬁed nearly all patients with
objective measured frailty with a sensitivity of 90%.20
In the sensitivity analysis, we found nonsigniﬁcant
associations of self-reported frailty and the individual
frailty components when NECOSAD was analyzed
separately. However, the effect measures were similar
in both separate cohorts, and an interaction term of the
original cohort with the several independent frailty
variables did not reach signiﬁcance. Therefore, we
argue that the associations of frailty with low UCrE
were not cohort-dependent.
The strengths of this study included that this was
the ﬁrst study that used a large general population-
based cohort as a control group to deﬁne low UCrE
values, adjusted for height, age, and sex. Second, this
was the ﬁrst study that evaluated associations of low
UCrE with self-reported frailty. UCrE values were
available in a large cohort of well-phenotyped patients
with advanced CKD. Furthermore, in the absence of
measured GFR, we used the mean of creatinine and urea
clearance, which is the best estimate of true GFR that is
clinically available in patients with advanced renal
failure.52
Our study should be interpreted in the light of
several limitations. First, using creatinine excretion
from 24-hour urine collections as a measure of muscle
mass might include collection errors. However, in all 3Kidney International Reports (2017) 2, 676–685
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and potential invalid collections were excluded.
Furthermore, we checked for possible invalid urine
collections in sensitivity analyses and found similar
results. Second, the GFR values that we used were
related to UCrE, because both were calculated from
creatinine in 24-hour urinary samples. However, using
the mean of urea and creatinine clearance for GFR
reduced this effect. Third, the shape of the UCrE
reference curve was extrapolated in the older age
values because the healthy cohort included younger
individuals compared with the patients with advanced
CKD in this study. Future studies should check
whether the UCrE reference curve is still accurate in
elderly patients (i.e., older than 75 years) with
advanced CKD. Fourth, because of the cross-sectional
design, any causal interpretation regarding the direc-
tion of the associations between low UCrE and self-
reported frailty could be considered only very care-
fully. Furthermore, low UCrE was deﬁned in a mainly
Caucasian population, which limited generalizability.
In contrast, this homogeneity of race might have led to
the elimination of potential complicating factors when
deriving thresholds for low UCrE, making the data
easier to understand. Finally, we used the EQ-5D as a
substitute for the frailty criterion of physical inactivity
and thereby presumed physical inactivity to be present
indirectly based on patients’ report of physical
disability and/or limitation. However, because the
Minnesota Leisure Time Activity questionnaire, which
was used by Fried et al. to deﬁne the physical inac-
tivity criterion, is frequently not available in large
cohorts, researchers have mostly used other deﬁnitions.
The physical inactivity criterion is probably the most
complicated to deﬁne and translate.53
This study provided an equation to deﬁne low UCrE
values for epidemiological research and clinical practice
for patients with advanced CKD. Although not
commonly used in the United States, collection of 24-
hour urine samples is routinely performed in Europe
in clinical care and is accepted as a valuable procedure
to assess kidney function and to estimate dietary
compliance to sodium (and protein) restricted diets. In
clinical practice, with 24-hour urine samples available,
low UCrE might be used to identify patients with
frailty and higher risk of adverse health outcomes, in
whom interventions could be initiated to improve
physical performance. Numerous studies demonstrated
that exercise has beneﬁcial effects on physical perfor-
mance and quality of life in patients with various
stages of CKD.54–57 These studies implied that exercise
may reverse certain aspects of frailty in CKD patients.
Whether low UCrE has an association with outcomesKidney International Reports (2017) 2, 676–685(e.g. mortality), independent of BMI and GFR in
advanced CKD patients needs to be investigated and is
beyond the scope of the present study.
In conclusion, lower kidney function is a strong
correlate of low UCrE, and self-reported frailty,
and the individual frailty components are associ-
ated with low UCrE as well, independent of
comorbidities.
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